– Thorough QT study: The company is the treatment in a randomized, double-blind, placebo-controlled, three-way, crossover study in about 54 healthy adults who to assess whether LEVADEX an effect on the QT interval was measured, completed electrocardiogram. The objectives of the study are to compare the acute effect of LEVADEX, moxifloxacin and placebo on the QT interval and assess the tolerability of a supratherapeutic dose of LEVADEX. The company expects to releasing results from this trial in the fourth quarter of 2010.
– Pharmacodynamics trial: This completed trial showed that there was no statistically significant difference between the LEVADEX orally inhaled migraine therapy and placebo groups in the primary endpoint of pulmonary artery pressure more than 2 hours after dosing. Pulmonary artery pressure in the IV DHE group was higher than both the LEVADEX and placebo groups. The PD study was a randomized, double-blind, It isontrolled, three-way, crossover study in healthy adults, comparing the acute effects of LEVADEX, IV DHE and placebo on pulmonary arterial pressure.The close collaboration between the scholarly fields and explorer at UNC offers great benefits on ‘outside-of – the-box thinking and new Centre is an outstanding example of how to specialists in multiple areas able join forces to meet new challenges, he said.